Interferon Alfa in Treating Patients With Newly Diagnosed Chronic Myelogenous Leukemia - Related Studies

Interferon Alfa in Treating Patients With Newly Diagnosed Chronic Myelogenous Leukemia

This study is ongoing, but not recruiting participants.

Study NCT00002869. Last updated on July 23, 2008. Information provided by National Cancer Institute (NCI)

Find Related Studies by Searching for the Conditions, Interventions, and Sponsors found in this study:


1	Conditions listed in this trial
		Leukemia

2	Additional conditions recognized in this trial
		Leukemia, Myelogenous, Chronic, BCR-ABL Positive
		Leukemia, Myeloid
		Leukemia, Myeloid, Chronic-Phase

3	More general conditions related to this trial
		Bone Marrow Diseases
		Hematologic Diseases
		Myeloproliferative Disorders
		Neoplasms
		Neoplasms by Histologic Type

4	Interventions listed in this trial
		cytarabine
		hydroxyurea
		recombinant interferon alfa

5	Additional drug interventions recognized in this trial
		Interferon Alfa-2a
		Interferon Alfa-2b
		Interferon Type I, Recombinant
		Interferon-alpha
		Interferons

6	More general drug interventions related to this trial
		Angiogenesis Inhibitors
		Angiogenesis Modulating Agents
		Anti-Infective Agents
		Antimetabolites
		Antimetabolites, Antineoplastic
		Antineoplastic Agents
		Antisickling Agents
		Antiviral Agents
		Enzyme Inhibitors
		Growth Inhibitors
		Growth Substances
		Hematologic Agents
		Immunologic Factors
		Immunosuppressive Agents
		Molecular Mechanisms of Pharmacological Action
		Nucleic Acid Synthesis Inhibitors
		Pharmacologic Actions
		Physiological Effects of Drugs
		Therapeutic Uses

7	Sponsors listed in this trial
		Medical Research Council